Table 2.
Evaluation of the effect of HFCWO on subpopulation (normosecretive vs hypersecretive) along time
| Normosecretive (n = 30) | Hypersecretive (n = 30) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| T0 | T1 | T2 | T3 | T0 | T1 | T2 | T3 | pvalue | |
| Not ventilated area (%) | 0.2 [0.0; 2.9] | 0.0 [0.0; 2.5] | 0.0 [0.0; 1.8] | 0.0 [0.0; 1.9] | 0.6 [0.0; 2.7] | 1.2 [0.0; 4.3] | 0.4 [0.0; 3.7] | 1.3 [0.0; 4.9] | 0.082 |
| TIV (mL) | 444 [345; 539] | 454 [372; 524] | 447 [374; 536] | 453 [358; 547] | 474 [364; 540] | 442 [363; 551] | 461 [363; 555] | 458 [363; 542] | 0.123 |
| Dorsal | 186 [142; 248] | 188 [131; 259] | 201 [132; 246] | 210 [119; 252] | 174 [143; 229] | 161 [133; 224] | 179 [145; 223] | 169 [134; 221] | 0.771 |
| Ventral | 222 [169; 325] | 248 [180; 319] | 242 [185; 310] | 234 [192; 307] | 291 [212; 351] | 285 [209; 360] | 278 [197; 361] | 281 [204; 336] | 0.150 |
| ΔTIV (mL) | 0 [0; 0] | 31 [− 28; 76] | − 7 [− 63; 65] | 11 [− 20; 34] | 0 [0; 0] | − 8 [− 38; 14] | − 3 [− 43; 34] | − 11 [− 44; 6] | 0.117 |
| Dorsal | 0 [0; 0] | 9 [− 11; 31] | 9 [− 37; 28] | 7 [− 10; 27] | 0 [0; 0] | − 3 [− 15; 12] | 4 [− 12; 17] | 2 [− 28; 17] | 0.408 |
| Ventral | 0 [0; 0] | 7 [− 15; 37] | 9 [− 28; 30] | 7 [− 23; 28] | 0 [0; 0] | − 4 [− 28; 9] | − 5 [− 36; 12] | − 9 [− 21; 8] | 0.204 |
| Centre of gravity (%) | 51.9 [48.9; 54.6] | 52.2 [49.8; 54.3] | 51.4 [49.9; 54.0] | 51.8 [48.6; 53.8] | 54.8 [51.7; 57.1] | 54.9 [51.6; 57.2] | 54.6 [52.3; 56.9] | 54.6 [51.5; 56.8] | 0.054 |
| ΔEELI (mL) | 0 [0; 0] | − 22 [− 144; 73] | − 167 [− 47; 36] | − 98 [− 207; 30] | 0 [0; 0] | 42 [− 46; 316] | 269 [92; 464]*,a | 131 [34; 453]*,b | < 0.001 |
| Dorsal | 0 [0; 0] | 9 [− 39; 75] | − 6 [− 85; 94] | − 13 [− 146; 94] | 0 [0; 0] | 11 [− 44; 231] | 97 [15; 431]*,a | 67 [11; 373]*,b | < 0.001 |
| Ventral | 0 [0; 0] | − 39 [− 134; 20] | −61 [−128; 12] | − 62 [− 188; 29] | 0 [0; 0] | 41 [− 60; 117] | 115 [7; 238]* | 59 [− 63; 194]* | < 0.001 |
| Heart rate (beat/min) | 84 (16) | 85 (18) | 84 (20) | 82 (18) | 80 (14) | 80 (14) | 77 (14) | 75 (13) | 0.916 |
| Mean arterial pressure (mmHg) | 86 (14) | 86 (15) | 85 (14) | 85 (14) | 88 (12) | 88 (13) | 85 (11) | 83 (11) | 0.811 |
| Respiratory rate (breath/min) | 18 (4) | 18 (4) | 18 (4) | 19 (4) | 18 (6) | 19 (6) | 19 (6) | 18 (6) | 0.954 |
| pH | 7.44 (0.06) | 7.42 (0.06) | 7.43 (0.06) | 7.43 (0.06) | 7.41 (0.06) | 7.41 (0.06) | 7.42 (0.05) | 7.42 (0.05) | 0.967 |
| PaCO2 (mmHg) | 40.9 (8.1) | 42.2 (8.1) | 41.7 (8.1) | 41.8 (7.8) | 44.3 (8.6) | 44.3 (9.4) | 43.7 (8.3) | 43.4 (8.3) | 0.952 |
| PaO2/FiO2 (mmHg) | 238 (75) | 234 (65) | 241 (61) | 239 (60) | 214 (56) | 219 (59) | 222 (55) | 220 (52) | 0.973 |
T0 baseline assessment, T1 assessment soon after the end of the treatment, T2 assessment 1 h after the end of the treatment, T3 assessment 3 h after the end of the treatment, TIV tidal impedance variation, ΔTIV difference of TIV from T0, ΔEELI difference of end-expiratory lung impedance from T0, PaCO2 arterial partial pressure of carbon dioxide, PaO2/FiO2 ratio between arterial partial pressure and inspired fraction of oxygen
*p < 0.05 normosecretive vs. hypersecretive within the same time point
ap < 0.05 T0 vs. T2 within the same subpopulation
bp < 0.05 T0 vs. T3 within the same subpopulation. All data are expressed as mean (standard deviation)